Big Buttons

• CALL TO ACTION: Tell FDA to deny drugmakers’ request

  Drugmakers are urging FDA to prohibit compounded GLP-1s. FDA needs to hear from you and your patients NOW! read more →

• APC to FDA: Just say no to Lilly

  This week APC's lawyers sent a formal comment to the FDA about Eli Lilly’s request that tirzepatide be added to the Demonstrably Difficult to Compound list. read more →

• California BOP sends proposed compounding regs to comment period

  The California State Board of Pharmacy decided to move the modified proposed sterile compounding regulations forward to a 30-day comment period. read more →

• Checking in on the post-Chevron fallout

  What’s happened in the world of federal regulation since the end of Chevron? read more →

• Hi, Noom!

  Welcome to our newest Bronze-level Corporate Patron, Noom! read more →

• PFMs can get 2.5% credit card processing

  A new benefit for APC’s Pharmacy/Facility Members: They may be able to cut their credit card processing fees to just 2.5% – 2.8%. read more →

• Phoenix compounders, rise!

  The latest of APC’s new regional meetings — CompoundED UpDATE — is coming to the Phoenix area December 5. read more →

• APC election results: directors and bylaws

  See the results of APC's elections, including four new directors and several changes to our bylaws. read more →

More News

A new APC workgroup is charged with developing guidance to help state boards of pharmacy interpret, implement and enforce USP 800. USP 800 provides guidelines for safe handling of hazardous drugs to minimize the risk of exposure for healthcare personnel, patients and the environment.

Chaired by Matt Martin, the group met for the first time this week to plan its work. The workgroup includes Cheri Kraemer; Jon Pritchett; Rad Dillon; John Herr; John Kim; Dave Rochefort; Kathleen Kane; and incoming APC Director of Public Policy Savannah Cunningham.

“We hope to provide boards of pharmacy thoughtful considerations about areas of USP 800 that have created significant discussion and/or concern for both pharmacists and some boards of pharmacy,” Martin said. “This USP chapter and its implementation will have a significant impact on patient access, the cost of healthcare and how healthcare is delivered across all disciplines of medicine based on how compliance is carried out. It is important that substantive discussions around the implementation of this chapter occur.”

The workgroup hopes to make its guidance resource available to boards of pharmacy in fall 2022.